On a relative basis, the stock has outperformed the S&P 500 by 3.11% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 0.26% in the last 1 week, and is up 7.62% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock. The stock has recorded a 20-day Moving Average of 4.92% and the 50-Day Moving Average is 3.22%.
Mallinckrodt plc (NYSE:MNK): The stock was completely flat for the day, closing at $62.45 on Friday. The flat closing masks the intraday volatility in the stock. After opening at $62.83, the stock touched an intraday high of $62.94 and a low of $62.00. Neither the bulls nor the bears asserted their supremacy at close, due to which the stock closed completely flat. The stock previously closed at $62.45. The total trading volume on Friday was 1,220,064.
The company Insiders own 0.53% of Mallinckrodt plc shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by 1.5% . Institutional Investors own 97.73% of Mallinckrodt plc shares. During last six month period, the net percent change held by insiders has seen a change of 3.83%. In a related news, The Securities and Exchange Commission has divulged in a Form 4 filing that the CFO of Mallinckrodt Plc, Harbaugh Matthew K had purchased shares worth of $29,685 in a transaction dated on May 10, 2016. A total of 500 shares were purchased at a price of $59.37 per share. The information is based on open market trades at the market prices.Option exercises are not covered.
Mallinckrodt public limited company (Mallinckrodt) is a global specialty pharmaceuticals company. The Company develops, manufactures, markets and distributes both branded and generic specialty pharmaceuticals, active pharmaceutical ingredients (API) and diagnostic imaging agents. The Company uses its API products in the manufacture of its generic pharmaceuticals and also sells them to other pharmaceutical companies. The Company operates through two segments: Specialty Pharmaceuticals and Global Medical Imaging. The Companys Specialty Pharmaceuticals segment develops, manufactures and sells, through its Brands business, drugs, including EXALGO (hydromorphone HCl) Extended-Release Tablets and GABLOFEN. The Companys Global Medical Imaging segment develops, manufactures and markets contrast media and delivery systems (CMDS). The Company offers INOMAX Total Care (inhaled nitric oxide), a neonatal critical care product.